A biomarker-based mathematical model to predict bone-forming potency of human synovial and periosteal mesenchymal stem cells by De Bari, C et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
A biomarker-based mathematical model to predict bone-forming
potency of human synovial and periosteal mesenchymal stem
cells
De Bari, C; Dell'Accio, F; Karystinou, A; Guillot, P V; Fisk, N M; Jones, E A;
McGonagle, D; Khan, I M; Archer, C W; Mitsiadis, T A; Donaldson, A N; Luyten, F
P; Pitzalis, C
De Bari, C; Dell'Accio, F; Karystinou, A; Guillot, P V; Fisk, N M; Jones, E A; McGonagle, D; Khan, I M; Archer,
C W; Mitsiadis, T A; Donaldson, A N; Luyten, F P; Pitzalis, C (2008). A biomarker-based mathematical model to
predict bone-forming potency of human synovial and periosteal mesenchymal stem cells. Arthritis and Rheumatism,
58(1):240-250.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Arthritis and Rheumatism 2008, 58(1):240-250.
De Bari, C; Dell'Accio, F; Karystinou, A; Guillot, P V; Fisk, N M; Jones, E A; McGonagle, D; Khan, I M; Archer,
C W; Mitsiadis, T A; Donaldson, A N; Luyten, F P; Pitzalis, C (2008). A biomarker-based mathematical model to
predict bone-forming potency of human synovial and periosteal mesenchymal stem cells. Arthritis and Rheumatism,
58(1):240-250.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Arthritis and Rheumatism 2008, 58(1):240-250.
A biomarker-based mathematical model to predict bone-forming
potency of human synovial and periosteal mesenchymal stem
cells
Abstract
OBJECTIVE: To develop a biomarker-based model to predict osteogenic potency of human
mesenchymal stem cells (MSCs) from synovial membrane and periosteum. METHODS: MSC
populations were derived from adult synovium and periosteum. Phenotype analysis was performed by
fluorescence-activated cell sorting and real-time reverse transcriptase-polymerase chain reaction
(RT-PCR). Telomere lengths were determined by Southern blot analysis. In vitro osteogenesis was
assessed quantitatively by measurements of alkaline phosphatase activity and calcium deposits. To
investigate bone formation in vivo, MSCs were seeded onto osteoinductive scaffolds and implanted
subcutaneously in nude mice. Bone was assessed by histology, and the human origin investigated by in
situ hybridization for human Alu genomic repeats. Quantitation was achieved by histomorphometry and
real-time RT-PCR for human osteocalcin. Analysis at the single-cell level was performed with clonal
populations obtained by limiting dilution. Multiple regressions were used to explore the incremental
predictive value of the markers. RESULTS: Periosteal MSCs had significantly greater osteogenic
potency than did synovial MSCs inherent to the single cell. Bone was largely of human origin in vivo.
Within the same tissue type, there was variability between different donors. To identify predictors of
osteogenic potency, we measured the expression levels of osteoblast lineage genes in synovial and
periosteal clonal MSCs prior to osteogenic treatment. We identified biomarkers that correlated with
osteogenic outcome and developed a mathematical model based on type I collagen and osteoprotegerin
expression that predicts the bone-forming potency of MSC preparations, independent of donor-related
variables and tissue source. CONCLUSION: Our findings indicate that our quality-control mathematical
model estimates the bone-forming potency of MSC preparations for bone repair.
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A Biomarker-Based Mathematical Model to Predict
Bone-Forming Potency of Human Synovial and
Periosteal Mesenchymal Stem Cells
Cosimo De Bari,1 Francesco Dell’Accio,1 Alexandra Karystinou,1 Pascale V. Guillot,2
Nicholas M. Fisk,2 Elena A. Jones,3 Dennis McGonagle,3 Ilyas M. Khan,4 Charles W. Archer,4
Thimios A. Mitsiadis,5 Ana Nora Donaldson,1 Frank P. Luyten,6 and Costantino Pitzalis1
Objective. To develop a biomarker-based model to
predict osteogenic potency of human mesenchymal stem
cells (MSCs) from synovial membrane and periosteum.
Methods. MSC populations were derived from
adult synovium and periosteum. Phenotype analysis was
performed by fluorescence-activated cell sorting and
real-time reverse transcriptase–polymerase chain reac-
tion (RT-PCR). Telomere lengths were determined by
Southern blot analysis. In vitro osteogenesis was as-
sessed quantitatively by measurements of alkaline phos-
phatase activity and calcium deposits. To investigate
bone formation in vivo, MSCs were seeded onto osteoin-
ductive scaffolds and implanted subcutaneously in nude
mice. Bone was assessed by histology, and the human
origin investigated by in situ hybridization for human
Alu genomic repeats. Quantitation was achieved by
histomorphometry and real-time RT-PCR for human
osteocalcin. Analysis at the single-cell level was per-
formed with clonal populations obtained by limiting
dilution. Multiple regressions were used to explore the
incremental predictive value of the markers.
Results. Periosteal MSCs had significantly
greater osteogenic potency than did synovial MSCs
inherent to the single cell. Bone was largely of human
origin in vivo. Within the same tissue type, there was
variability between different donors. To identify predic-
tors of osteogenic potency, we measured the expression
levels of osteoblast lineage genes in synovial and peri-
osteal clonal MSCs prior to osteogenic treatment. We
identified biomarkers that correlated with osteogenic
outcome and developed a mathematical model based on
type I collagen and osteoprotegerin expression that
predicts the bone-forming potency of MSC prepara-
tions, independent of donor-related variables and tissue
source.
Conclusion. Our findings indicate that our
quality-control mathematical model estimates the bone-
forming potency of MSC preparations for bone repair.
Increasing evidence supports the clinical use of
stem cells for tissue repair. A major concern is the large
structural and clinical variability in outcome. Such vari-
ability is at least partly due to donor-related factors and
the inconsistency of stem cell preparations. This prob-
lem has been highlighted by the recent publication of
contrasting results in clinical trials of cardiac cell therapy
(1).
The known osteogenic capacity of mesenchymal
stem cells (MSCs) (2–5) makes bone repair a natural
application of MSC preparations. MSC-based ap-
proaches to bone repair would circumvent clinical com-
plications associated with the use of autologous bone
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grafts, such as donor site morbidity and the long-term
discomfort that accompanies bone harvest. Transplanta-
tion of allogeneic bone is also used, but is subject to
disease transmission and host rejection. Proof-of-
concept studies in humans support the clinical utility of
MSCs for bone repair (6–8). The incorporation of MSCs
into osteoinductive scaffolds accelerates the formation
of bone with biomechanical properties equivalent to
bone grafts in vivo (9).
Donor-associated factors and MSC preparation
protocols influence the bone-forming capacity of MSCs
(10). In addition, MSCs isolated from different tissues
have distinct differentiation properties (11–15). The
resulting variability limits standardization of MSC-based
approaches to bone repair and impedes comparison of
clinical study outcomes. There is, therefore, a pressing
clinical need for assays that allow quantitative estimation
of the bone-forming potency of MSC preparations. Such
potency assays would allow development of quality
controls for efficacy of MSC preparations (16,17), a
prerequisite for routine use in clinical practice.
In this study, we analyzed the variability in osteo-
genic potency of matched human MSC preparations
from synovial membrane (SM) and periosteum and
identified biomarkers that, using a mathematical for-
mula modeled on the quantitative outcome of 2 inde-
pendent assays of bone formation, predict the bone-
forming potency of MSC preparations independently of
donor-related variables and tissue source.
MATERIALS AND METHODS
Cell isolation and culture. Samples of human perios-
teum (wet weight 10–50 mg) were harvested aseptically from
the proximal medial tibia of 4 donors of various ages (24, 36,
58, and 83 years). Random biopsies of SM (wet weight 10–50
mg) were obtained aseptically from the knee joints of the same
4 donors. All specimens were obtained within 12 hours after
death. Donors had no history of knee joint disorders and did
not have active infections or tumors. Periosteal and synovial
specimens from each donor were processed in parallel using
the same protocol, as previously described (5). Cells were
isolated and expanded in monolayer on plastic in growth
medium (high-glucose Dulbecco’s modified Eagle’s medium
[DMEM; Life Technologies, Gaithersburg, MD] containing
10% fetal bovine serum [selected lot from Life Technologies]
and antibiotics [Life Technologies]) (5).
Cell cloning. Cell cloning was performed by limiting
dilution as described elsewhere (4). First-passage synovial and
periosteal cells were suspended in growth medium and plated
at a density of 0.5 cells/well in 96-well, flat-bottomed culture
plates. Cell populations arising from single cells were subcul-
tured upon reaching confluence with serial 1:4 dilution pas-
sages.
Telomere length assay. Genomic DNA was extracted
from passage 7 periosteal and synovial MSC monolayers using
a standard protocol, and telomere lengths were determined
semiquantitatively by Southern blotting using TeloTAGGG
telomere length assay, according to the recommendations of
the manufacturer (Roche, Indianapolis, IN). Mean telomere
length was determined as described previously (18).
Phenotyping of culture-expanded MSCs using 3-color
flow cytometry. Culture-expanded (passage 4 to passage 6)
MSCs were used for flow cytometry at 105 cells/test. Test
antibodies were as follows: phycoerythrin (PE)–conjugated
low-affinity nerve growth factor receptor (LNGFR)/p75,
CD106 (vascular cell adhesion molecule 1), CD146 (Muc18),
CD166 (activated leukocyte cell adhesion molecule), CD73/
SH3 (all from PharMingen, San Diego, CA), CD105/SH2
(Serotec, Oxford, UK), fluorescein isothiocyanate (FITC)–
conjugated CD45 (Dako, Carpinteria, CA), and CD13 (Sero-
tec). D7-FIB–PE was labeled in-house from purified D7-FIB
(Serotec). Hybridoma cells B4-78 against bone and liver iso-
forms of alkaline phosphatase were obtained from the Devel-
opmental Studies Hybridoma Bank (Iowa City, IA). Hybrid-
oma supernatant was produced in-house, and antibody
labeling was detected using secondary goat anti-mouse FITC
(Serotec). Isotype-specific negative control antibodies were
purchased from Serotec. Dead cells were gated out based on
propidium iodide exclusion (Sigma, St. Louis, MO). All flow
cytometry data were analyzed with WinMDI, version 8 soft-
ware (Scripps Research Institute, La Jolla, CA).
In vitro osteogenesis. The in vitro osteogenesis assay
was performed as described previously (5). Alkaline phospha-
tase activity was determined colorimetrically as described
previously (4), using a commercially available kit (Thermo
Electron Corporation, Waltham, MA). Protein content was
determined by the Bradford method (Bio-Rad, Richmond,
CA), using bovine serum albumin (Sigma) as standard. Alka-
line phosphatase activity was expressed as arbitrary units per
microgram of protein content. To determine calcium content,
cell layers were rinsed twice with phosphate buffered saline
and scraped off the dish in 0.5N HCl. The cell layers were
extracted by shaking for 4 hours at 4°C, were centrifuged at
1,000g for 5 minutes, and the supernatant was used for calcium
determination using a commercially available kit, according to
the recommendations of the manufacturer (Thermo Electron
Corporation). Total calcium was calculated from standard
solutions and expressed as micrograms per microgram of
protein content (determined in parallel wells).
In vivo osteogenesis. Animal experiments were per-
formed in compliance with the UK Home Office and the
Ethics Committee for Animal Research at the Katholieke
Universiteit. MSCs were seeded onto the osteoinductive Col-
lagraft matrix (NeuColl, Campbell, CA) and implanted subcu-
taneously into nude mice as described previously (4). Briefly,
3-mm3 Collagraft cubes were wetted in DMEM, blotted onto a
gauze compress, and immersed into 50 l of MSC suspension
(105 cells/l in growth medium) to allow attachment of the
cells to the Collagraft matrix. After 1 hour of incubation at
37°C, cells that did not attach to the Collagraft matrix but
remained in suspension in the medium were counted and
subtracted from the total number of seeded cells (5 million) to
calculate the seeding efficiency as the percentage of cells that
remained in the Collagraft matrix after 1 hour of incubation.
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The seeding efficiency was independent of cell type and
routinely varied between 40% and 70%. The cell–Collagraft
constructs were implanted subcutaneously into nude mice. At
different time points postimplantation, mice were killed, and
the constructs dissected. The explants were then cut in two,
and one half was used for total RNA extraction and the other
fixed overnight in 4% formaldehyde. Fixed samples were
decalcified overnight in Decal (Serva, Heidelberg, Germany),
paraffin-embedded, and sectioned (into 7-m–thick sections)
at 3 different levels.
Histology and bone histomorphometry. Sections were
stained with hematoxylin and eosin (H&E) and then assessed
qualitatively for the presence of bone tissue and quantitatively
by bone histomorphometry. For each section, the total area
and the area covered with bone tissue were measured using
Scion Image (Scion, Frederick, MD). The amount of bone
tissue was then calculated as a percentage of the total implant
area.
In situ hybridization for human-specific Alu genomic
repeats. In situ hybridization for human Alu genomic repeats
was performed as described previously (19,20).
Total RNA extraction and reverse transcriptase–
polymerase chain reaction (RT-PCR) analysis. Explants were
homogenized in TRIzol reagent (Life Technologies) using a
Polytron homogenizer. Total RNA was isolated using TRIzol,
according to the recommendations of the manufacturer. After
DNase treatment, complementary DNA (cDNA) samples
were obtained by reverse transcription of 2 g of total RNA
(ThermoScript; Life Technologies) using oligo(dT)20 as
primer. Real-time quantitative PCR was carried out with
SYBR Green using the Opticon real-time PCR cycler (MJ
Research, San Francisco, CA). Gene expression of human cells
within mouse tissue was evaluated using primers specific for
human cDNA samples as described previously (4,21,22).
Mouse bone was used to ensure specificity of the primers for
human cDNA samples. Primer sequences are listed in
Table 1.
Statistical analysis. Each assessment was performed
on 2 or 3 cultures or constructs per cell source. Parametric data
were analyzed using Student’s t-test and are presented as the
mean  SD. Analysis of variance with Bonferroni adjustment
for multiple comparisons was used to evaluate alkaline phos-
phatase activity over time in SM MSCs versus periosteal
MSCs. Multiple regressions were used to explore the incre-
mental predictive value of the markers, taking into account any
significant interactions. Polynomial and logarithmic transfor-
mations of the markers were explored. Agreement of the
measurements of calcium with the model was assessed using
mixed linear regressions, to account for the effect of the donor,
as well as the Bland and Altman method and intraclass
Table 1. Primers used for real-time RT-PCR analysis and sizes of PCR products*
Gene Primer sequence Amplicon (bp)
-actin Forward 5-CACGGCTGCTTCCAGCTC-3 134
Reverse 5-CACAGGACTCCATGCCCAG-3
GAPDH Forward 5-AACAGCGACACCCACTCCTC-3 85
Reverse 5-CATACCAGGAAATGAGCTTGACAA-3
Runx2 Forward 5-GCAGCACGCTATTAAATCCAAATT-3 115
Reverse 5-GGCACGAAGGCTCATCATTC-3
Osterix Forward 5-CCCCACCTCTTGCAACCA-3 102
Reverse 5-GGCTCCACCACTCCCTTCTAG-3
ALP Forward 5-CCCTTGACCCCCACAATGT-3 80
Reverse 5-GTTGTTCCTGTTGACCTCGTACTG-3
Type I collagen Forward 5-CAGCCGCTTCACCTACAGC-3 85
Reverse 5-TTTTGTATTCAATCACTGTCTTGCC-3
OPG Forward 5-GTGGACCACCCAGGAAACG-3 132
Reverse 5-CGGTCTTCCACTTTGCTGTACAG-3
Osteonectin Forward 5-TCTTCCCTGTACACTGGCAGTTC-3 115
Reverse 5-AACTGCTCCATGGGGATGGA-3
Osteopontin Forward 5-GCCGACCAAGGAAAACTCACTA-3 107
Reverse 5-CAGAACTTCCAGAATCAGCCTGTT-3
Osteocalcin Forward 5-CCTCACACTCCTCGCCCTATT-3 117
Reverse 5-CCCTCCTGCTTGGACACAAA-3
BSP Forward 5-AAACGAAGAAAGCGAAGCAGAA-3 94
Reverse 5-GCTGCCGTTGCCGTTTT-3
* RT-PCR  reverse transcriptase–polymerase chain reaction; ALP  alkaline phosphatase; OPG 
osteoprotegerin; BSP  bone sialoprotein.
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correlation coefficients (ICCs), and 95% confidence intervals
(95% CIs) were calculated.
RESULTS
Greater bone-forming potency of MSCs from
periosteum than from synovium. We quantified the
osteogenic potency of matched human MSC prepara-
tions from SM and periosteum. In vitro, passage 7 SM
MSCs and periosteal MSCs were treated with osteogenic
medium for 20 days and assessed for alkaline phospha-
tase activity at different time points. In both MSC
populations, there was a significant increase in alkaline
phosphatase activity, which peaked on day 8 and then
returned to almost basal levels by day 20 (Figure 1A). A
first important source of variability that we identified
was the tissue of origin of MSCs. Indeed, at all time
Figure 1. Osteogenic potency of synovial membrane (SM) mesenchymal stem cells (MSCs) and periosteal (Pe) MSCs. A and B, Osteogenesis in
vitro. Human SM MSCs and periosteal MSCs were treated with osteogenic medium. Alkaline phosphatase (ALP) activity (A) was determined on
days 0, 4, 8, 12, and 20, and MSC calcium deposition (B) was determined (in parallel wells) on days 0 and 20. Values are the mean SD of 4 donors.
C–L, Bone formation in vivo. MSCs from 3 donors (ages 24, 36, and 83 years) were seeded onto Collagraft scaffolds, and the constructs implanted
subcutaneously into nude mice. C, Hematoxylin and eosin (H&E) staining of SM MSCs 8 weeks after implantation. D, Higher-magnification view
of the boxed area in C. E, H&E staining of periosteal MSCs 8 weeks after implantation. F, Higher-magnification view of the boxed area in E. G,
Representative photomicrograph of an in situ hybridization for human Alu genomic repeats of a periosteal MSC construct at 8 weeks, counterstained
with eosin. Inset, In situ hybridization for human Alu genomic repeats of mouse bone tissue used as a control, counterstained with eosin. Human
nuclei are stained black. No nuclear counterstaining was performed, and therefore, Alu-negative nuclei are not visible. Bars  100 m. H,
Quantification of the results of real-time quantitative reverse transcriptase–polymerase chain reaction for human osteocalcin (hOC) normalized to
human -actin. Expression of human OC was monitored in MSC monolayers and at 4 and 8 weeks after implantation of the constructs. The primers
used were specific for human cDNA. The bone marker OC was barely detectable in the monolayer cultures, but OC levels increased progressively
after 4 and 8 weeks in vivo. At both time points examined, the levels of human OC in periosteal MSC constructs were significantly higher than the
levels in SM MSC constructs. Values are the mean  SD of 3 donors. I, Quantification of in vivo bone formation assessed by histomorphometry.
Values are the mean  SD of 3 donors. J, Correlation between percent bone area and expression of human OC (normalized to human -actin) at
8 weeks in vivo. K, Correlation between micrograms of calcium per microgram of protein content at 20 days in vitro and percent bone area at 8 weeks
in vivo. L, Correlation between micrograms of calcium per microgram of protein content at 20 days in vitro and expression of human OC (normalized
to human -actin) at 8 weeks in vivo. Values in J–L are the mean.   P  0.05;   P  0.01, versus SM MSCs.
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points except days 0 and 20, periosteal MSCs displayed
significantly higher levels of alkaline phosphatase activ-
ity than did SM MSCs (Figure 1A). By day 20, calcium
deposits were significantly higher in periosteal MSCs
than in SM MSCs (Figure 1B). Under similar conditions,
human dermal fibroblasts failed to undergo osteogenesis
(data not shown). These data indicate greater osteogenic
potential of periosteal MSCs than SM MSCs in vitro.
To investigate whether the difference in osteo-
genic potential was dependent on in vitro conditions, we
examined the capacity of SM MSCs and periosteal
MSCs to form bone in vivo. We used an established
assay consisting of seeding cells onto osteoinductive
Collagraft scaffolds (composed of hydroxyapatite, trical-
cium phosphate, and type I collagen, routinely used in
orthopedic clinical practice) and implanting the con-
structs under the skin of immunodeficient nude mice
(4,20). The seeding efficiency of SM MSCs and perios-
teal MSCs into Collagraft scaffolds was comparable
(40–70%), with no correlation between MSC seeding
efficiency and bone formation in vivo. Histologically, no
bone was evident at 4 weeks. At 8 weeks, areas of woven
bone were observed after H&E staining of both SM
MSC–seeded (Figures 1C and D) and periosteal MSC–
seeded scaffolds (Figures 1E and F).
In contrast, no bone was retrieved from empty
scaffolds or scaffolds seeded with expanded human
dermal fibroblasts (data not shown), indicating that
human MSCs are necessary for bone formation in vivo
under these conditions. In situ hybridization for human
Alu genomic repeats demonstrated that human nuclei
were present within bone areas in both SM MSC and
periosteal MSC constructs (Figure 1G).
To confirm differentiation of human MSCs into
an osteoblast phenotype at the molecular level, we
monitored the expression of human osteocalcin (OC) by
quantitative real-time RT-PCR using human-specific
primers. The levels of human OC messenger RNA
(mRNA), normalized to human -actin, were signifi-
cantly higher in the periosteal MSC constructs at both 4
and 8 weeks (Figure 1H), indicating that periosteal
MSCs had greater osteogenic potential in vivo than did
SM MSCs.
To quantify bone formation, we measured the
bone area in serial sections of MSC constructs by
histomorphometry, following H&E staining. At 8 weeks,
the percent area occupied by bone was significantly
higher in periosteal MSC constructs than in SM MSC
constructs (Figure 1I). The levels of OC mRNA de-
tected with human-specific primers were significantly
higher in periosteal MSC than in SM MSC implants
(Figure 1H) and correlated significantly with the percent
bone area (gradient 121.4 [95% CI 112, 131]; R2 
0.997, P  0.000) (Figure 1J).
A second source of variability within each tissue
was related to the individual donor. The coefficients of
variation of OC expression levels and percent bone area
in vivo were 55% and 90% for SM MSCs and 36% and
41% for periosteal MSCs, respectively. This interindi-
vidual variability was not due to unreliable measure-
ments, since within each sample, the values of OC
expression and percent bone area, obtained using 2
independent systems, displayed a high degree of corre-
lation (Figure 1J).
Calcium deposition (normalized to protein con-
tent) after 20 days of osteogenic treatment in vitro
correlated significantly with both percent bone area
(gradient 0.015 [95% CI 0.01, 0.02]; R2  0.941, P 
0.0000) (Figure 1K) and expression levels of human OC
(normalized to human -actin; gradient 0.0001 [95% CI
0.0001, 0.0002]; R2  0.944, P  0.001) (Figure 1L) at 8
weeks in vivo. This indicates that, under our experimen-
tal conditions and at the specified time points, calcium
deposition (normalized to protein content) in the in
vitro osteogenesis assay was sufficient to measure osteo-
genic outcome quantitatively.
No significant differences in growth potential
and cell phenotype between synovial and periosteal
MSCs. Growth potential and cell phenotype could ac-
count for the differential bone-forming capacities of
MSC populations (23). During culture expansion, the
growth curves of SM MSCs and periosteal MSCs from
the 4 donors tested overlapped and remained linear over
at least 30 population doublings (Figure 2A). As ex-
pected, and consistent with the findings of our previous
studies (4,5), there was a progressive age-associated
decline in the growth rate of MSCs, which was compa-
rable for both SM MSCs and periosteal MSCs (Figures
2B and C). We then determined semiquantitatively the
length of the telomeres of SM MSCs and periosteal
MSCs at passage 7, when the osteogenesis assays were
carried out. Despite undetectable telomerase activity
(4,5), the telomeres of the human MSC populations
tested were long, comparable with those of an immor-
talized cell line, irrespective of donor age, and with no
significant difference between the 2 tissue sources (Fig-
ure 2D). The mean  SD telomere length was 11.50 
0.53 for SM MSCs and 11.45 0.47 for periosteal MSCs
(P  0.86).
Next, we compared the phenotype of the ex-
panded human MSCs using fluorescence-activated cell
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sorting. Both synovial and periosteal cell populations
displayed the conventional MSC phenotype (3,24,25),
with no significant difference in the expression levels of
the cell surface markers tested (Figure 2E). Histograms
are shown in Supplementary Figure 1, available on the
Arthritis & Rheumatism Web site at http://www.mrw.
interscience.wiley.com/suppmat/0004-3591/suppmat/. As
expected, CD45, a marker of hematopoietic lineage
cells, was not detected in any of the MSC samples tested.
Expression of CD73, CD166, CD105, CD13, and D7-
FIB was detected uniformly in all MSC samples. CD146
and CD106 displayed variable expression between do-
nors, with no correlation with donor age. LNGFR was
undetectable in expanded MSCs (Figure 2E), consistent
with findings reported for MSCs from human bone
marrow (24). To exclude osteoblast contamination or
early osteogenic commitment of MSC populations, we
analyzed the cell surface expression levels of the osteo-
blast lineage marker alkaline phosphatase (26,27). Both
synovial and periosteal MSCs were negative for alkaline
phosphatase (Figure 2E), consistent with the notion that
they were undifferentiated MSCs with no detectable
commitment to the osteogenic lineage.
Osteogenic potency in single-cell–derived clonal
populations. MSC populations were expanded as poly-
clonal cultures. Thus, the different osteogenic capacities
Figure 2. Growth potential and phenotype of SM MSCs and periosteal MSCs. A, Kinetics of growth of MSCs from 4 donors. The kinetics of growth
were analyzed starting with the first passage. The growth curves overlapped and remained linear up to 30 population doublings, with no significant
difference between SM MSCs and periosteal MSCs. B and C, Age-associated decline in the growth rates of SM MSCs (B) and periosteal MSCs (C).
D, Southern blot analysis of telomeres. Expanded MSCs from 3 donors of different ages were analyzed by Southern blot analysis to determine the
length of their telomeres. Regardless of donor age, the telomere lengths were comparable, with no significant difference between SM MSCs (S) and
periosteal MSCs (P). The U937 cell line was used as a positive control (high molecular weight [HMW]; mean telomere length 10.2 kb), and HL-60
cells were used as a negative control (low molecular weight [LMW]; mean telomere length 3.9 kb). Mmolecular weight marker. E, Surface marker
phenotype of human MSCs following culture expansion. Values are the mean  SD of 4 donors. Both SM MSCs and periosteal MSCs displayed
high self-renewal capacity and a conventional MSC phenotype, and there was no significant difference between the 2 tissue sources. LNGFR 
low-affinity nerve growth factor receptor (see Figure 1 for other definitions).
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of SM MSCs and periosteal MSCs could either result
from variability in cell subset compositions of these
possibly mixed cell populations or be inherent to the
single MSC. To address this, we compared the osteo-
genic potency of single-cell–derived clonal populations
obtained by limiting dilution from both synovium and
periosteum. Of a total of 91 clones analyzed, 31 stopped
growing prior to 10 population doublings. The remaining
60 clones displayed heterogeneous proliferation poten-
tial in vitro (Figure 3A).
To eliminate the bias of different growth rates
and to compare like with like, we selected 8 clones (4 SM
and 4 periosteal clones; 1 clone per tissue per donor)
that displayed similar and efficient growth curves (Fig-
ure 3B) and similar telomere lengths (Figure 3C).
Mean SD telomere length was 7.08 0.63 for synovial
clones and 7.53  0.18 for periosteal clones (P  0.23).
As assessed by flow cytometry, expanded clonal popula-
tions displayed the conventional MSC phenotype (rep-
resentative histograms are shown in Supplementary Fig-
ure 2, available on the Arthritis & Rheumatism Web site
at http://www.mrw.interscience.wiley.com/suppmat/
0004-3591/suppmat/). All selected clones were multipo-
tent, capable of chondrogenic, osteogenic, and adipo-
genic differentiation in vitro (data not shown). After 22
population doublings, and while still in the linear phase
of their growth curves, the clonal cell populations were
assessed quantitatively for their capacity to undergo
osteogenesis in vitro. Periosteal clones displayed a sig-
nificantly greater osteogenic potential than did SM
clones, as determined by alkaline phosphatase activity
(Figure 3D) and calcium deposition (Figure 3E), indi-
cating that the superior osteogenic potency of periosteal
MSCs is intrinsic to the single multipotent MSC.
To investigate the molecular basis of this differ-
ential osteogenic potency and to identify potential pre-
dictors of osteogenic outcome, we examined the expres-
sion levels of osteoblast lineage genes in both SM MSC
and periosteal MSC clonal populations prior to osteo-
genic treatment. The expression levels of type I collagen,
osteoprotegerin (OPG), osteonectin, and osteopontin,
normalized to GAPDH, were significantly higher in the
periosteal clones than in the synovial clones, whereas
there was no significant difference in the expression
levels of runt-related transcription factor 2, osterix,
alkaline phosphatase, bone sialoprotein, or OC (Figure
3F). The basal expression levels of osteoblast lineage
genes in clonal MSCs were log scales lower than in
periosteal MSCs after full osteogenic differentiation in
the Collagraft scaffold in vivo (Figure 3F), indicating
that prior to osteogenic treatment, neither synovial nor
Figure 3. Comparison of SM MSCs and periosteal MSCs at the
single-cell level. A, Proliferation potential of synovial and periosteal
clones. Sixty clones were analyzed for their cumulative production of
cells. A marked variation in proliferative capacity between individual
clones is evident. B, Kinetics of growth of 8 selected single-cell–derived
clonal MSCs from synovium and periosteum (1 clone per tissue type
per donor). The growth curves were linear and overlapped. C, South-
ern blot analysis showing telomere lengths of the 4 selected SM clones
and 4 selected periosteal clones. M  molecular weight marker. D,
ALP activity on days 0 and 8 of treatment with osteogenic medium in
vitro. Values are the mean  SD of the 4 selected SM clones and 4
selected periosteal clones.  P 0.01 versus SM MSCs. E, Calcium
deposition on days 0 and 20. Values are the mean  SD of the 4
selected SM clones and 4 selected periosteal clones. Periosteal clones
displayed significantly greater osteogenic potential than did synovial
clones.   P  0.01 versus SM MSCs. F, Quantification of the re-
sults of real-time quantitative reverse transcriptase–polymerase chain
reaction for osteoblast lineage genes normalized to human GAPDH
in the selected culture-expanded synovial and periosteal single-
cell–derived clonal populations, prior to osteogenic treatment. Data
are expressed on a logarithmic scale.   P  0.01 versus SM MSCs.
RUNX-2  runt-related transcription factor 2; F  human dermal
fibroblasts (negative control); B  human periosteal MSC–Collagraft
construct containing bone tissue (8 weeks in vivo), used as a reference
for expression levels of osteoblast markers; col1  type I collagen;
OPG osteoprotegerin; ON osteonectin; OP osteopontin; OC
osteocalcin; BSP  bone sialoprotein (see Figure 1 for other defini-
tions).
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periosteal clonal MSCs displayed an osteoblast pheno-
type.
A biomarker-based mathematical model to pre-
dict MSC osteogenic potency. Capitalizing on these
results, we endeavored to identify predictors of osteo-
genic potency of MSCs that would be independent of the
tissue source and of the donor. To this end, we evaluated
the correlations between the basal gene expression levels
in the 8 selected (4 synovial and 4 periosteal) clonal
MSCs prior to osteogenic treatment and the values of
calcium deposition at 20 days of osteogenic treatment in
vitro (Table 2). In a multiple linear regression model
(R2  98%; adjusted 98%) of the individual markers
studied, type I collagen proved to be the most important
predictor, followed by OPG. Although the bivariate
correlation between calcium and OPG was moderate
(R2  0.36), a curve fitting exercise indicated a strong
quadratic trend (R2  0.91), thus confirming OPG as a
valid predictor. Calcium increased on average by 0.43
(95% CI 0.3, 0.53; P  0.000) for each unit increase in
type I collagen and by 0.012 (95% CI 0.001, 0.02; P 
0.04) for each unit increase in OPG. The derived model
was as follows:
Calcium/proteins 0.70 0.43 (type I collagen/GAPDH)
 0.012 (OPG/GAPDH)
There was no interaction with the type of clonal
MSC population, indicating that this model can predict
osteogenic outcome regardless of the tissue of origin of
MSCs.
The model showed excellent agreement with the
actual calcium scale (Figure 4A). The Bland and Altman
plot (Figure 4B) proved that the bias was independent of
the level of calcium assessed (the ICC was 98%). The
estimate of the average discrepancy in relation to the
actual calcium scale was 0.01, with an SD of 0.09,
yielding 95% limits of agreement of 0.07 (95% CI
0.08, 0.06) to 0.09 (95% CI 0.08, 0.10).
DISCUSSION
Several studies have demonstrated the therapeu-
tic utility of MSCs in humans (6–8,28–31). However,
donor-related variability and inconsistency of MSC
preparations limit standardization and impede compar-
isons of clinical study outcomes. In this proof-of-concept
study, we proposed a strategy for tackling this problem.
We developed a simple mathematical model based on
the expression of only 2 biomarkers, type I collagen and
OPG, which predicts the osteogenic potency of adult
human MSC preparations from synovium and perios-
teum, independently of donor-related variables and tis-
sue source.
The mathematical model was obtained using
single-cell–derived clonal populations. As with clonal
populations, periosteal polyclonal MSCs displayed a
significantly greater osteogenic potency than did syno-
vial polyclonal MSCs. However, within each tissue
source of MSCs, there was no statistically significant
difference in the osteogenic outcome between poly-
clonal and clonal cell populations. In spite of this, when
we applied the mathematical model to polyclonal syno-
vial or periosteal MSC populations, it yielded an ICC of
25%, thus showing low predictive power. In addition, it
was not possible to generate by regression analysis any
model predictive of the osteogenic outcome of poly-
clonal cell populations, at least with the molecular
markers tested. A possible explanation is that in poly-
Figure 4. Analysis of the mathematical model predicting osteogenic
outcome. A, Plot of calcium predicted with the model versus calcium
measured, and line of equality. B, Bland and Altman plot of the
difference (measured minus predicted; bias) versus the average (mea-
sured and predicted). Triangles represent SM MSCs, and circles
represent periosteal MSCs. See Figure 1 for definitions.
Table 2. Correlation of gene expression levels with calcium
deposition*
Gene R P
Runx2 0.108 0.400
Osterix 0.164 0.349
ALP 0.463 0.124
Type I collagen 0.973 0.000
OPG 0.598 0.059
Osteonectin 0.904 0.001
Osteopontin 0.322 0.218
Osteocalcin 0.923 0.001
BSP 0.338 0.206
* Basal expression levels of osteoblast lineage genes in clonal mesen-
chymal stem cells prior to osteogenic treatment, and levels of calcium
deposition (normalized to protein content) at 20 days of osteogenic
treatment in vitro were measured, and correlations determined. See
Table 1 for definitions.
MATHEMATICAL MODEL PREDICTING MSC OSTEOGENIC POTENCY 247
clonal mixed cell populations, noncompetent, nonclono-
genic cells would influence the overall gene expression
prior to osteogenic treatment, but are subsequently lost
during selective osteogenic conditions. In support of this
hypothesis, in the osteogenic cultures a large proportion
of cells underwent apoptosis within the first few days of
treatment, resulting in the selection of a subpopulation
that underwent osteogenesis (data not shown).
As reported with single-cell–derived colonies of
bone marrow–derived stromal cells (32–34), synovial
and periosteal clonal populations became hetero-
geneous during culture expansion, as determined by flow
cytometry for the cell surface markers tested (Supple-
mentary Figure 2). Nonetheless, the growth curves and
the osteogenic outcomes of individual clonal popula-
tions were distinct, and it was possible to predict their
osteogenic potential using molecular markers. The phe-
notypic heterogeneity within each clonal population may
be due to the different functional status of the individual
cells of the single-cell progeny (e.g., different phases of
the cell cycle, symmetric or asymmetric cell division, or
different stages of differentiation). However, in spite of
the phenotypic heterogeneity during culture expansion,
clones would maintain distinct, possibly inherent bio-
logic features. The coexistence, in different proportions,
of clones with diverse osteogenic potential within the
same polyclonal population would result in a variability
too complex to be predicted by our marker analysis.
We are aware that the use of clonal populations
in the clinic would be impractical and costly, and there-
fore, we do not advocate the use of our model for quality
control of MSC populations for clinical use with the
current technologies. However, our biomarker-based
model represents a biologic platform upon which to
devise strategies for the prospective purification of MSC
subpopulations with predictable and consistent bone-
forming potency independently of the donor and tissue
source. Such purification, which could be either from
fresh synovial/periosteal tissue digests or from expanded
polyclonal cell populations, would not only increase the
consistency of MSC preparations for clinical use, but
also facilitate the estimation of their potency by using
biomarkers, thus allowing standardization of therapeutic
protocols using MSCs.
Periosteal MSCs formed more bone in vivo than
did SM MSCs, as determined by histomorphometry. The
bone tissue retrieved appeared to be largely of human
origin. Although we do not exclude contribution of the
mouse host to bone formation in vivo, the difference in
bone amount is unlikely to be solely due to periosteal
MSCs having a greater capacity for recruiting mouse
host osteoprogenitor cells, since the levels of OC mRNA
detected with human-specific primers were significantly
higher in periosteal MSC implants than in SM MSC
implants and correlated significantly with the percent
bone area. Notably, no bone was retrieved from empty
scaffolds or scaffolds seeded with expanded human
dermal fibroblasts, indicating that human MSCs are
necessary for bone formation in vivo under these exper-
imental conditions.
The development of a biomarker-based model
that predicts the bone-forming potency of human MSC
preparations is of considerable clinical relevance. It may
facilitate the selection of individuals that qualify for an
MSC-based bone repair approach. It may also help
identify the best source and preparation protocol of
human MSCs or adjust the dose in bone-forming MSC
units from patient to patient. It remains to be investi-
gated whether the same formula can be applied to MSC
preparations from other tissue sources, such as bone
marrow, or to any other stem cell preparations, whether
embryonic, fetal, or adult. We predict that, in addition to
the properties intrinsic to the cell preparation, other
factors such as inflammation, biomechanics, and patient
comorbidity will influence orthotopic bone formation
and clinical outcome. Preclinical studies and clinical
trials of bone repair using MSC-based protocols will thus
be necessary for prospective validation of our potency
assays and related model.
The generation of consistent MSC-based thera-
peutic protocols is a prerequisite for translating these
technologies into routine clinical application. There is
evidence that MSCs from mismatched donors could be
poorly immunogenic in recipients in some in vivo sys-
tems (35,36). Also, the induction of tolerance to alloge-
neic stem cells is a field of intense investigation (37).
Once the immunologic barriers are overcome, potency
assays and related quality control measures will provide
a solid basis for establishing batches of certified stem cell
products with specific clinical indications for allogeneic
transplantation. This approach will increase consistency
and decrease costs of MSC therapies, thus accelerating
translation to routine clinical use.
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Clinical Image: Fibrodysplasia ossificans progressiva seen on three-dimensional computed tomography
The patient, a 28-year-old woman, was admitted to our hospital with trismus, abnormal soft tissue tumors, and diffuse ankylosis of
the limbs and trunk. These symptoms had progressed following 2 surgeries, 19 years and 23 years previously. Whole-body
3-dimensional computed tomography scanning revealed diffuse calcification over the soft tissue of the neck, both arms, chest wall,
and left thigh. The patient was diagnosed as having fibrodysplasia ossificans progressiva, a rare inherited disease characterized by
progressive soft tissue ossification occurring after minor injuries. Three-dimensional computed tomography can be a useful tool for
diagnosis of this condition.
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